(Q33836477)

29 July 2017

1 reference

title

Managing the adverse effects of interferon-beta therapy in multiple sclerosis (English)

1 reference

29 July 2017

0 references

A Bayas

1

1 reference

29 July 2017

P Rieckmann

series ordinal

2

1 reference

29 July 2017

publication date

1 February 2000

1 reference

29 July 2017

1 reference

29 July 2017

volume

22

1 reference

29 July 2017

issue

2

1 reference

29 July 2017

page(s)

149-159

1 reference

https://scigraph.springernature.com/pub.10.2165/00002018-200022020-00006

29 July 2017

exact match

0 references

cites work

Mood disorder and multiple sclerosis

1 reference

12 December 2020

Delayed occurrence of a severe cutaneous reaction in a multiple sclerosis patient taking interferon beta-1b

1 reference

12 December 2020

Pentoxifylline, a phosphodiesterase inhibitor, induces immune deviation in patients with multiple sclerosis

1 reference

12 December 2020

A case of cutaneous necrosis during interferon-beta 1b (B-IFN) therapy in multiple sclerosis

1 reference

12 December 2020

Onset of myasthenia gravis in a patient with multiple sclerosis during interferon-1b treatment

1 reference

12 December 2020

Suicide and multiple sclerosis: an epidemiological investigation

1 reference

12 December 2020

Autoimmune events during interferon beta-1b treatment for multiple sclerosis

1 reference

12 December 2020

Interferon beta-1b effects on cytokine mRNA in peripheral mononuclear cells in multiple sclerosis

1 reference

12 December 2020

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

12 December 2020

The role of liver in the catabolism of human alpha- and beta-interferon

1 reference

12 December 2020

Cutaneous reactions to recombinant human interferon beta-1b: the clinical and histologic spectrum

1 reference

12 December 2020

No increase of serum autoantibodies during therapy with recombinant human interferon-beta1a in relapsing-remitting multiple sclerosis

1 reference

12 December 2020

Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group

1 reference

12 December 2020

Amelioration of flulike symptoms at the onset of interferon β- 1b therapy in multiple sclerosis by low-dose oral steroids is related to a decrease in interleukin-6 induction

1 reference

12 December 2020

No evidence for increased frequency of autoantibodies during interferon-beta1b treatment of multiple sclerosis.

1 reference

12 December 2020

Treatment of depression improves adherence to interferon beta-1b therapy for multiple sclerosis

1 reference

12 December 2020

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

1 reference

12 December 2020

[Therapy of multiple sclerosis with interferon-beta-1b. Educating the patient and managing side-effects]

1 reference

12 December 2020

Depression and multiple sclerosis

1 reference

12 December 2020

Cutaneous necrosis associated with recombinant interferon injection. Report of three cases with interferon beta-1b and review of the literature.

1 reference

12 December 2020

An open-labelled assessment of adverse effects associated with interferon 1-beta in the treatment of multiple sclerosis.

1 reference

12 December 2020

Practice advisory on selection of patients with multiple sclerosis for treatment with Betaseron. Report of the Quality Standards Subcommittee of the American Academy of Neurology

1 reference

12 December 2020

Therapeutic expectations of patients with multiple sclerosis upon initiating interferon beta-1b: relationship to adherence to treatment

1 reference

12 December 2020

Cause of death in patients attending multiple sclerosis clinics

1 reference

12 December 2020

Großflächige kutan-subkutane Infiltrate als Nebenwirkung von Interferon-beta-Injektion

1 reference

12 December 2020

Granulomatous dermatitis with focal sarcoidal features associated with recombinant interferon beta-1b injections

1 reference

12 December 2020

Subacute cutaneous lupus erythematosus associated with interferon beta-1a

1 reference

12 December 2020

Exacerbations of multiple sclerosis in patients treated with gamma interferon

1 reference

12 December 2020

Effects of interferon beta-1B in rheumatoid arthritis: a case report

1 reference

12 December 2020

Autoimmune hyperthyroidism in patients with multiple sclerosis treated with interferon beta-1b

1 reference

12 December 2020

Low-dose steroids reduce flu-like symptoms at the initiation of IFNbeta-1b in relapsing-remitting MS.

1 reference

12 December 2020

Interferon-gamma-secreting cells in multiple sclerosis patients treated with interferon beta-1b

1 reference

12 December 2020

Necrotizing cutaneous lesions caused by interferon beta injections in a patient with multiple sclerosis

1 reference

12 December 2020

New onset of rheumatoid arthritis during interferon beta-1B treatment in a patient with multiple sclerosis: comment on the case report by Jabaily and Thompson

1 reference

12 December 2020

Severe vaginal bleeding associated with recombinant interferon beta-1B

1 reference

12 December 2020

Severe Raynaud's phenomenon associated with interferon-beta treatment for multiple sclerosis

1 reference

12 December 2020

Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS

1 reference

12 December 2020

Occurrence of thyroid autoimmunity and dysfunction throughout a nine-month follow-up in patients undergoing interferon-beta therapy for multiple sclerosis

1 reference

12 December 2020

Interferon beta-1b injection site reactions and necroses

1 reference

12 December 2020

Management of patients receiving interferon beta-1b for multiple sclerosis: report of a consensus conference

1 reference

12 December 2020

Interferon treatment for multiple sclerosis: autoimmune complications may be lethal

1 reference

12 December 2020

The phosphodiesterase inhibitor pentoxifylline reduces early side effects of interferon-beta 1b treatment in patients with multiple sclerosis

1 reference

12 December 2020

Managing side effects of interferon-beta in patients with relapsing-remitting multiple sclerosis

1 reference

12 December 2020

[Multiple sclerosis: therapy with recombinant beta-1b interferon: initial results with 30 multiple sclerosis patients in northwest Switzerland]

1 reference

12 December 2020

Interferon-beta1A-induced polyarthritis in a patient with the HLA-DRB1*0404 allele

1 reference

12 December 2020

Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group

1 reference

12 December 2020

Cutaneous ulcerations and pustular psoriasis flare caused by recombinant interferon beta injections in patients with multiple sclerosis

1 reference

12 December 2020

Side effect profile of interferon beta-1b in MS: results of an open label trial

1 reference

12 December 2020

Synergistic immunomodulatory effects of interferon-beta1b and the phosphodiesterase inhibitor pentoxifylline in patients with relapsing-remitting multiple sclerosis

1 reference

12 December 2020

10.2165/00002018-200022020-00006

Identifiers

DOI

1 reference

Dimensions Publication ID

29 July 2017

1017267054

0 references

1 reference